Catabasis Pharmaceuticals adds $14.5M to Series A financing

Wed, 12/08/2010 - 4:33am
Mass High Tech: The Journal of New England Technology

Catabasis Pharmaceuticals Inc., a Cambridge biopharmaceutical company focused on inflammatory and metabolic diseases, has raised $14.5 million in a second tranche of a Series A funding round led by SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, with additional backing from Advanced Technology Ventures. The Series A financing originally closed with $39.6 million in April.

The second tranche of financing stems from development milestones Catabasis reached, in leading to human clinical trials, for its drug candidate to treat type 2 diabetes. The funds will support this compound in reaching human clinical trials in 2011, in addition to supporting the company’s metabolic disease and inflammation programs.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.